Giotrif, overall survival benefit for patients with EGFR mutation-positive non-small cell lung cancer
The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has issued a positive opinion for an update to the European label for Giotrif ( Afatinib ), strengt ...
read article